Chronic Kidney Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Jiangsu HengRui, Disc Medicine, 3SBio, Kind Pharma, Jiangsu Hansoh Pharm

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Kidney Disease pipeline constitutes 75+ key companies continuously working towards developing 80+ Chronic Kidney Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Kidney Disease Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Kidney Disease Market.

The Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Chronic Kidney Disease Pipeline Report:

*
Companies across the globe are diligently working toward developing novel Chronic Kidney Disease treatment therapies with a considerable amount of success over the years.

*
Chronic Kidney Disease companies working in the treatment market are Maze Therapeutics, Alebund Pharmaceuticals, AdAlta, Lisata Therapeutics, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AstraZeneca, Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others, are developing therapies for the Chronic Kidney Disease treatment

*
Emerging Chronic Kidney Disease therapies in the different phases of clinical trials are- Research Program, AP 304, AD-214, CLBS201, Tirzepatide, HRS-1780, BI-685509, Baxdrostat, DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others are expected to have a significant impact on the Chronic Kidney Disease market in the coming years.

*
In August 2025, Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company dedicated to advancing therapies for kidney diseases, announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,377,082 for UNI-494 in the treatment of Chronic Kidney Disease (CKD). This latest patent expands upon an earlier method-of-use patent that covered UNI-494 for treating Acute Kidney Injury.

*
In May 2025, Bayer announced a study aimed at evaluating the effectiveness of different doses of BAY3283142, when combined with standard CKD treatment, in reducing urinary albumin levels in participants with chronic kidney disease. The study will compare changes in the urine albumin-creatinine ratio (UACR) after 16 weeks between BAY3283142 and a placebo.

*
In May 2025, AstraZeneca carried out a Phase IV trial to evaluate the efficacy and safety of dapagliflozin in preventing the progression of chronic kidney disease in adult patients in China.

*
In April 2025, UC Davis Health initiated a new cell therapy clinical trial targeting patients with chronic kidney disease (CKD). This innovative therapy aims to potentially restore kidney function in individuals with renal impairment caused by type 2 diabetes. In the United States, approximately one in seven people is affected by CKD, with diabetic kidney disease (DKD) being the leading cause. CKD occurs when the kidneys are damaged and unable to effectively filter blood, leading to a buildup of waste and fluids in the body, which can result in serious complications such as high blood pressure, heart disease, stroke, and premature death.

*
In June 2024, Novo Nordisk announced that the Phase III CLARION-CKD trial did not meet its primary endpoint and that it will record an impairment loss of approximately DKK 5.7 billion for the intangible asset ocedurenone in the second quarter of 2024.

*
In May 2024, In the landmark FLOW trial, semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, demonstrated substantial benefits in reducing the risk of major kidney disease, cardiovascular events, and mortality in patients with chronic kidney disease (CKD) and type 2 diabetes.

*
In March 2024, Akebia Therapeutics Registered , Inc. (Nasdaq: AKBA), a biopharmaceutical company dedicated to improving the lives of individuals affected by kidney disease, has announced that the U.S. Food and Drug Administration (FDA) has granted approval for Vafseo Registered (vadadustat) Tablets. This medication is indicated for the treatment of anemia resulting from chronic kidney disease (CKD) in adults undergoing dialysis for a minimum of three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor administered once daily, which triggers the body's response to hypoxia to stimulate natural erythropoietin production, thereby managing anemia. Vafseo has received approval in 37 countries.

Chronic Kidney Disease Overview

Chronic Kidney Disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to filter waste and excess fluids from the blood. This leads to a buildup of toxins in the body, causing health problems such as high blood pressure, anemia, weak bones, and nerve damage. CKD often develops due to underlying conditions like diabetes or hypertension. It progresses through five stages, with end-stage kidney disease requiring dialysis or a kidney transplant. Early detection and management can slow its progression and reduce complications.

Get a Free Sample PDF Report to know more about Chronic Kidney Disease Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight [https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Emerging Chronic Kidney Disease Drugs Under Different Phases of Clinical Development Include:

*
Research Program: Maze Therapeutics

*
AP 304: Alebund Pharmaceuticals

*
AD-214: AdAlta

*
CLBS201: Lisata Therapeutics

*
Tirzepatide: Eli Lilly and Company

*
HRS-1780: Shandong Suncadia Medicine

*
BI-685509: Boehringer Ingelheim

*
Baxdrostat: AstraZeneca

*
DDO-3055: Jiangsu HengRui Medicine

*
DISC: 0974 Disc Medicine

*
SSS 17: 3SBio

*
AND017: Kind Pharmaceuticals

*
Pegol-Sihematide: Jiangsu Hansoh Pharmaceuticals

*
Efepoetin alfa: Genexine

Chronic Kidney Disease Route of Administration

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

*
Oral

*
Parenteral

*
Intravenous

*
Subcutaneous

*
Topical

Chronic Kidney Disease Molecule Type

Chronic Kidney Disease Products have been categorized under various Molecule types, such as

*
Monoclonal Antibody

*
Peptides

*
Polymer

*
Small molecule

*
Gene therapy

Chronic Kidney Disease Pipeline Therapeutics Assessment

*
Chronic Kidney Disease Assessment by Product Type

*
Chronic Kidney Disease By Stage and Product Type

*
Chronic Kidney Disease Assessment by Route of Administration

*
Chronic Kidney Disease By Stage and Route of Administration

*
Chronic Kidney Disease Assessment by Molecule Type

*
Chronic Kidney Disease by Stage and Molecule Type

DelveInsight's Chronic Kidney Disease Report covers around 80+ products under different phases of clinical development like

*
Late-stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I)

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

*
Route of Administration

Further Chronic Kidney Disease product details are provided in the report. Download the Chronic Kidney Disease pipeline report to learn more about the emerging Chronic Kidney Disease therapies [https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key companies in the Chronic Kidney Disease Therapeutics Market include:

Key companies developing therapies for Chronic Kidney Disease are - FibroGen Inc, FortuneRock (China) Ltd, General Biologics Inc, Genexine Inc, Great Bay Bio Holdings Ltd, GSK plc, 3SBio Inc, Akebia Therapeutics Inc, Avesthagen Ltd, Biocad, Chong Kun Dang Pharmaceutical Corporation, Dong-A Socio Holdings Co Ltd, Jiangsu Hengrui Medicine Co Ltd, Liminal BioSciences Inc, Panacea Biotec Ltd, Panion & Bf Biotech Inc, PharmaEssentia Corp, PhytoHealth Corp, Jiangsu Hansoh Pharmaceutical Group Co Ltd, UBI Pharma Inc, Uni-Bio Science Group Ltd, Xenetic Biosciences Inc, Zosano Pharma Corp, Shanghai Chemo Wanbang Biopharma Co Ltd, SunBio Inc, HEC Pharma Co Ltd, HK inno.N Corp, Imagine Pharma LLC, InSilico Medicine, Japan Tobacco Inc, Jecho Biopharmaceuticals Co Ltd, Zydus Lifesciences Ltd, and others.

Chronic Kidney Disease Pipeline Analysis:

The Chronic Kidney Disease pipeline report provides insights into

*
The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.

*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.

*
Chronic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Chronic Kidney Disease drugs and therapies [https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Chronic Kidney Disease Pipeline Market Drivers

*
Increase in the geriatric population with a higher risk of renal anemia due to age-related renal issues, increase in research and developmental activities are some of the important factors that are fueling the Chronic Kidney Disease Market.

Chronic Kidney Disease Pipeline Market Barriers

*
However, high-cost associated with the disease, side effects associated with the disease and other factors are creating obstacles in the Chronic Kidney Disease Market growth.

Scope of Chronic Kidney Disease Pipeline Drug Insight

*
Coverage: Global

*
Key Chronic Kidney Disease Companies: Maze Therapeutics, Alebund Pharmaceuticals, AdAlta, Lisata Therapeutics, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AstraZeneca, Jiangsu HengRui Medicine, Disc Medicine, 3SBio, Kind Pharmaceuticals, Jiangsu Hansoh Pharmaceuticals, Genexine, and others

*
Key Chronic Kidney Disease Therapies: Research Program, AP 304, AD-214, CLBS201, Tirzepatide, HRS-1780, BI-685509, Baxdrostat, DDO-3055, DISC 0974, SSS 17, AND017, Pegol-Sihematide, Efepoetin alfa, and others

*
Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies

*
Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers

Request for Sample PDF Report for Chronic Kidney Disease Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Chronic Kidney Disease Report Introduction

2. Chronic Kidney Disease Executive Summary

3. Chronic Kidney Disease Overview

4. Chronic Kidney Disease- Analytical Perspective In-depth Commercial Assessment

5. Chronic Kidney Disease Pipeline Therapeutics

6. Chronic Kidney Disease Late Stage Products (Phase II/III)

7. Chronic Kidney Disease Mid Stage Products (Phase II)

8. Chronic Kidney Disease Early Stage Products (Phase I)

9. Chronic Kidney Disease Preclinical Stage Products

10. Chronic Kidney Disease Therapeutics Assessment

11. Chronic Kidney Disease Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Chronic Kidney Disease Key Companies

14. Chronic Kidney Disease Key Products

15. Chronic Kidney Disease Unmet Needs

16 . Chronic Kidney Disease Market Drivers and Barriers

17. Chronic Kidney Disease Future Perspectives and Conclusion

18. Chronic Kidney Disease Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-kidney-disease-pipeline-2025-fda-updates-therapy-innovations-and-clinical-trial-landscape-analysis-by-delveinsight-jiangsu-hengrui-disc-medicine-3sbio-kind-pharma-jiangsu-hansoh-pharm]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.